Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. [electronic resource]
Producer: 20161213Description: 673-9 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Disease-Free Survival
- Esophageal Neoplasms -- drug therapy
- Esophagogastric Junction -- drug effects
- Female
- Humans
- Male
- Middle Aged
- Paclitaxel -- administration & dosage
- Quality of Life
- Treatment Outcome
- Ramucirumab
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.